Cook Medical is engaged in two clinical studies that will provide additional data on the safety and effectiveness of inferior vena cava (IVC) filters.
The Accreditation for Cardiovascular Excellence (ACE) Board of Directors has approved a new set of Performance Metrics for Cath PCI Accreditation.
Biotronik has expanded its line of reinforced introducer sheaths.
Providing exceptional cardiovascular care for patients to achieve the best possible outcomes is the number one goal for ...
The U.S. Food and Drug Administration (FDA) recently cleared BB Medical Surgical’s Thixo-Gel, which is sprayed on to the patient to enable quicker and easier ultrasound scans.
Medtronic Inc. announced CE mark and launch of the NC Euphora noncompliant balloon dilatation catheter.
Strokes kill nearly 130,000 Americans every year, according to the Centers for Disease Control and Prevention. Because approximately 30 percent of strokes are caused by blockages in the carotid arteries — the blood vessels that supply blood to the brain— successful treatment of carotid disease could save thousands of them, according to the Society for Vascular Surgery, members of which will discuss and debate treatment options for carotid disease at the 2014 Vascular Annual Meeting, taking place June 4-7 at the Hynes Convention Center in Boston.
Cardiac positron emission tomography (PET) is growing in popularity among cardiologists because it provides the ability ...
June 3, 2014 — Edwards Lifesciences Corp. received CE mark for the advanced Edwards Intuity Elite valve system. The next-generation, rapid deployment system facilitates smaller incisions in surgical aortic valve replacement (AVR) procedures, and is built upon extensive evidence supporting the durability of the Carpentier-Edwards Perimount heart valve design.
June 3, 2014 — JenaValve Technology Inc., a privately held, venture-backed developer of transcatheter aortic valve implantation (TAVI) systems for the treatment of aortic valve disease, announced the results of the JenaValve EvalUation of Long Term Performance and Safety In PaTients with SEvere AoRtic Stenosis (JUPITER) registry at EuroPCR in Paris.
June 3, 2014 — The U.S. Food and Drug Administration (FDA) announced it approved Zontivity (vorapaxar) tablets to reduce the risk of heart attack, stroke, cardiovascular death and need for procedures to restore the blood flow to the heart in patients with a previous heart attack or blockages in the arteries to the legs.
When performing radiofrequency (RF) ablation to treat cardiac arrhythmia, medical professionals must balance the safety ...
St. Jude Medical announced the completion of its acquisition of the privately held CardioMEMS Inc., developer of the CardioMEMS heart failure (HF) management system. The acquisition was completed on May 30, 2014.
As more endovascular medical programs adapt simulation as an essential part of their training curriculum, there is a constant and consistent need for updated simulation solutions. Simbionix is offering two new platforms and two training modules, to enhance hands-on training for more clinicians to enhance patient safety and improve clinical outcomes.
June St. Jude Medical Inc. announced preliminary results from the EnligHTN III study, which found the company’s second-generation EnligHTN renal denervation system provided safe and effective therapy for patients with drug-resistant, uncontrolled hypertension six months post-procedure.
Change Healthcare Cardiology Hemodynamics is an integrated hemodynamic monitoring system for monitoring vital signs and ...
MedInformatix announced at the annual meeting of the Society for Imaging Informatics in Medicine (SIIM) that it is bringing its next-generation technology to clients using its provider and patient portal applications integrated with OneDX software.
New research has found that bariatric surgery is an effective way to control weight in morbidly obese patients who are at risk for developing atrial fibrillation (AF). Bariatric or weight loss surgery is an operation on the stomach that limits food intake and is typically recommended for patients who are unable to lose weight on their own through diet and exercise.
Direct Flow Medical has received investigational device exemption (IDE) approval from the U.S. Food and Drug Administration (FDA) to initiate the pivotal phase of the SALUS trial. The SALUS trial is a prospective, non-randomized, multicenter, core lab adjudicated clinical trial, evaluating the Direct Flow Medical transcatheter aortic valve system at up to 30 sites.